922510-92-7 Usage
Uses
Used in Pharmaceutical Industry:
(2-chloro-5-Methylphenyl)hydrazine hydrochloride is used as a synthetic intermediate for the development of various pharmaceuticals. Its role in the synthesis process is crucial for creating active pharmaceutical ingredients that can be used in the formulation of drugs targeting different health conditions.
Used in Agrochemical Industry:
In the agrochemical sector, (2-chloro-5-Methylphenyl)hydrazine hydrochloride is utilized as a building block in the creation of agrochemicals. These chemicals are essential for developing pesticides, herbicides, and other products that contribute to enhancing crop protection and agricultural productivity.
Used in Cancer Research:
(2-chloro-5-Methylphenyl)hydrazine hydrochloride is employed as a research compound in the field of cancer research. Its biological activities make it a candidate for studying its potential as a therapeutic agent against cancer. (2-chloro-5-Methylphenyl)hydrazine hydrochloride's properties are investigated to understand its mechanisms of action and its possible use in developing novel cancer treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 922510-92-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,2,5,1 and 0 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 922510-92:
(8*9)+(7*2)+(6*2)+(5*5)+(4*1)+(3*0)+(2*9)+(1*2)=147
147 % 10 = 7
So 922510-92-7 is a valid CAS Registry Number.
922510-92-7Relevant academic research and scientific papers
Extended Benzamide Derivatives as Modulators of the EP2 Receptor
-
Page/Page column 19, (2010/03/02)
The present invention relates to extended benzamide derivatives of the general formula I, to processes for preparation thereof and to use thereof for production of pharmaceutical compositions for treatment of disorders and indications associated with the
Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists
-
Page/Page column 22, (2010/11/25)
The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I
